Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment

P Dongiovanni, QM Anstee… - Current pharmaceutical …, 2013 - ingentaconnect.com
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …
被引用次数：282 相关文章
[PDF] psu.edu

[PDF][PDF] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, QM Anstee, L Valenti - Current Pharmaceutical Design, 2013 - Citeseer
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …
[PDF] scienceopen.com

[PDF][PDF] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, QM Anstee… - Current Pharmaceutical …, 2013 - scienceopen.com
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …

Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment

P Dongiovanni, QM Anstee, L Valenti - CURRENT PHARMACEUTICAL …, 2013 - air.unimi.it
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …
[PDF] academia.edu

[PDF][PDF] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, QM Anstee, L Valenti - Current Pharmaceutical …, 2013 - academia.edu
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …

[引用][C] Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment

P Dongiovanni, QM Anstee, L Valenti - Current Pharmaceutical …, 2013 - eprints.ncl.ac.uk
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response
to treatment - ePrints - Newcastle University Newcastle University Toggle Main Menu Toggle …

[引用][C] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, Q Anstee, L Valenti - Current Pharmaceutical Design, 2013 - cir.nii.ac.jp
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and
Response to Treatment | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

[引用][C] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P DONGIOVANNI, QM ANSTEE… - Current pharmaceutical …, 2013 - pascal-francis.inist.fr
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and
Response to Treatment CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, QM Anstee, L Valenti - Current Pharmaceutical …, 2013 - hero.epa.gov
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …
[PDF] researchgate.net

[PDF][PDF] Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

P Dongiovanni, QM Anstee… - Current Pharmaceutical …, 2013 - researchgate.net
Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver
disease (NAFLD) which, when associated with oxidative hepatocellular damage …